CCCC C4 Therapeutics Inc
Price (delayed)
$1.52
Market cap
$107.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.52
Enterprise value
$114.72M
C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment
Highlights
CCCC's gross profit has surged by 71% year-on-year and by 6% since the previous quarter
The company's revenue has surged by 71% YoY and by 6% QoQ
C4 Therapeutics's equity has decreased by 12% YoY and by 11% QoQ
The quick ratio has declined by 11% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of CCCC
Market
Valuations
Earnings
Shares outstanding
70.99M
Market cap
$107.9M
Enterprise value
$114.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
2.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
Revenue
$35.58M
Gross profit
$35.58M
Operating income
-$119.61M
Net income
-$105.32M
EBIT
-$105.19M
EBITDA
-$96.95M
Free cash flow
-$65.34M
Per share
Balance sheet
Liquidity
EPS
-$1.52
EPS diluted
-$1.52
Free cash flow per share
-$0.94
Book value per share
$3.06
Revenue per share
$0.51
TBVPS
$5.04
Total assets
$349.6M
Total liabilities
$133.62M
Debt
$65.76M
Equity
$215.99M
Working capital
$212.59M
Debt to equity
0.3
Current ratio
5.71
Quick ratio
5.57
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
-272.4%
Gross margin
100%
Net margin
-296%
Operating margin
-336.1%
Return on assets
-28%
Return on equity
-43.7%
Return on invested capital
-32.7%
Return on capital employed
-34.6%
Return on sales
-295.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CCCC stock price
How has the C4 Therapeutics stock price performed over time
Intraday
5.92%
1 week
-17.84%
1 month
-43.91%
1 year
-80.21%
YTD
-57.78%
QTD
-5%
Financial performance
How have C4 Therapeutics's revenue and profit performed over time
Revenue
$35.58M
Gross profit
$35.58M
Operating income
-$119.61M
Net income
-$105.32M
Gross margin
100%
Net margin
-296%
CCCC's gross profit has surged by 71% year-on-year and by 6% since the previous quarter
The company's revenue has surged by 71% YoY and by 6% QoQ
The company's net margin has surged by 54% YoY and by 6% QoQ
The operating margin has grown by 50% YoY and by 5% from the previous quarter
Growth
What is C4 Therapeutics's growth rate over time
Valuation
What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
0.5
P/S
2.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
The EPS has increased by 43% year-on-year and by 11% since the previous quarter
The price to book (P/B) is 80% lower than the 5-year quarterly average of 2.4 and 71% lower than the last 4 quarters average of 1.6
C4 Therapeutics's equity has decreased by 12% YoY and by 11% QoQ
CCCC's price to sales (P/S) is 86% less than its 5-year quarterly average of 20.3 and 81% less than its last 4 quarters average of 14.4
The company's revenue has surged by 71% YoY and by 6% QoQ
Efficiency
How efficient is C4 Therapeutics business performance
The return on sales has surged by 53% year-on-year and by 5% since the previous quarter
The company's return on assets rose by 22% YoY
C4 Therapeutics's ROE has increased by 21% YoY but it has decreased by 3.1% from the previous quarter
C4 Therapeutics's return on invested capital has increased by 16% YoY and by 3% QoQ
Dividends
What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CCCC.
Financial health
How did C4 Therapeutics financials performed over time
C4 Therapeutics's total assets is 162% more than its total liabilities
The quick ratio has declined by 11% year-on-year and by 10% since the previous quarter
The current ratio is down by 10% YoY and by 10% QoQ
The company's debt is 70% lower than its equity
C4 Therapeutics's equity has decreased by 12% YoY and by 11% QoQ
CCCC's debt to equity is up by 7% since the previous quarter and by 3.4% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.